Eli Lilly & Co. stock (US5324571083): Retevmo Phase 3 lung cancer data draws focus to US pharma heavyweight

Eli Lilly & Co. shares on the New York Stock Exchange are drawing investor attention after the United States-based pharmaceutical group released new Phase 3 data for its cancer drug Retevmo in early-stage RET fusion-positive non-small cell lung cancer, a development that adds another potential growth pillar to its portfolio alongside obesity and diabetes treatments, according to a company press release dated 05/31/2026 from Indianapolis.

In the LIBRETTO-432 trial, Eli Lilly reported that adjuvant therapy with Retevmo (selpercatinib) reduced the risk of disease recurrence or death by 83% compared with placebo in patients with stage II–IIIA RET fusion-positive non-small cell lung cancer, meeting the primary endpoint of investigator-assessed event-free survival, as detailed in the 05/31/2026 announcement.

At a median follow-up of 24 months in the primary analysis population of 109 patients with stage II–IIIA disease, the company stated that the event-free survival rate at 24 months was 92% for selpercatinib versus 61% for placebo, while the hazard ratio of 0.17 with a 95% confidence interval of 0.06 to 0.51 and a p-value of less than 0.001 underscored the statistical significance of the result.

Eli Lilly also highlighted that in the broader LIBRETTO-432 study population of 151 patients with stage IB–IIIA disease, event-free survival continued to favor selpercatinib with the same hazard ratio of 0.17 and a 95% confidence interval of 0.06 to 0.49, and the 24-month event-free survival rate reached 94% for the selpercatinib group compared with 70% in the placebo arm, reinforcing the potential of the drug in earlier-stage lung cancer.

The company noted in its 05/31/2026 communication that median event-free survival was not yet reached for patients on selpercatinib in the primary analysis population, while the median for the placebo group was 31.8 months, suggesting a durable benefit signal that will be important for regulators, clinicians, and payers evaluating adjuvant use of the RET inhibitor.

Retevmo is already approved in the United States for certain patients with metastatic RET fusion-positive non-small cell lung cancer and other RET-altered cancers, and Eli Lilly indicated that it intends to discuss the LIBRETTO-432 results with global health authorities, including the US Food and Drug Administration, potentially opening a path to expand the label into the adjuvant setting.

Alongside the efficacy findings, Eli Lilly provided safety data showing that interstitial lung disease or pneumonitis occurred in 1.8% of patients treated with Retevmo in its broader clinical program, with 0.3% experiencing Grade 3 or 4 events and 0.3% experiencing fatal reactions, and the company emphasized the need for careful monitoring and treatment interruption if such events arise.

The 05/31/2026 release also reminded prescribers of hypersensitivity risks, citing signs and symptoms such as fever, rash, joint or muscle pain and laboratory abnormalities, and advised that in patients who develop hypersensitivity, treatment with Retevmo should be withheld and corticosteroid therapy initiated, with discontinuation mandated in cases of severe reactions such as Stevens-Johnson Syndrome reported in post-marketing experience.

Serious adverse reactions were reported in 44% of patients who received Retevmo in the LIBRETTO-001 study, with events such as pneumonia, pleural effusion, abdominal pain, hemorrhage, hypersensitivity, dyspnea and hyponatremia occurring in at least 2% of treated patients, while in the LIBRETTO-431 trial, serious adverse reactions occurred in 35% of patients, and 4.4% experienced fatal events, including myocardial infarction and respiratory failure, according to Eli Lilly’s safety summary.

The company described the available Retevmo formulations as 40 mg and 80 mg capsules as well as 40 mg, 80 mg, 120 mg and 160 mg tablets, indicating dosage flexibility for physicians tailoring regimens to individual patient needs based on weight, tolerability and co-morbidities, as detailed in its product information.

From a US market perspective, Eli Lilly is one of the largest constituents of the S&P 500 health care sector and trades on the New York Stock Exchange under the ticker LLY, with the stock recently quoted above USD 1,100 per share on the NYSE in late May 2026 according to exchange data, keeping the company among the highest-valued global pharmaceutical groups by market capitalization.

According to data cited by MarketBeat in an update accessed on 05/31/2026, Eli Lilly shares opened at USD 1,105.37 on the NYSE on a recent Friday session, while the same source pointed to an average analyst price target of USD 1,227.00 and a consensus rating of Moderate Buy across its covered institutions, placing the current trading level moderately below the aggregated target.

MarketBeat’s 05/31/2026 coverage also referenced a research note from Morgan Stanley dated 05/01/2026, in which the US investment bank reiterated an overweight stance on Eli Lilly and set a price objective of USD 1,344.00, underscoring the degree to which Wall Street’s large brokers remain focused on the company’s pipeline assets, including novel oncology and metabolic compounds.

In parallel, institutional investor activity around Eli Lilly shares has continued, with recent filings cited by MarketBeat on 05/31/2026 showing that Nomura Asset Management Co. Ltd. increased its position to more than 700,000 shares and Mitchell Capital Management Co. lifted its holdings by over 40% in the fourth quarter, signaling that both large global asset managers and smaller active managers remain engaged with the stock.

For investors in Germany, Eli Lilly stock is also available via secondary trading lines such as Tradegate and Frankfurt in euros, where the share price typically tracks the primary US listing adjusted for the EUR/USD exchange rate, although liquidity and spreads can differ from the NYSE order book conditions.

As the LIBRETTO-432 data emerged around the American Society of Clinical Oncology congress timing, specialty media such as Pharmaphorum noted on 05/31/2026 that the results position Retevmo to extend its reach into early-stage lung cancer, where adjuvant therapies are increasingly competitive and can materially influence long-term survival outcomes in defined biomarker-positive subgroups.

The strengthening of Eli Lilly’s oncology pipeline with Retevmo comes as the Indianapolis-based company continues to benefit from strong demand for its incretin-based diabetes and obesity drugs, providing a diversified growth profile that spans metabolic disease and oncology and underpins the attention the company receives from US and international investors.

As of: 05/31/2026

By the editorial team - specialized in equity coverage.

Eli Lilly & Co.: core business model

Eli Lilly is a US-based research-driven pharmaceutical group that focuses on discovering, developing, manufacturing and marketing branded prescription medicines across areas such as metabolic disease, oncology, immunology and neuroscience, with revenue primarily generated from blockbuster diabetes and obesity therapies, established immunology drugs and a growing portfolio of targeted cancer treatments.

Chart technicals and 52-week range

Looking at the New York Stock Exchange listing, Eli Lilly’s share price has traded in a wide 52-week range in 2025 and 2026 as the market reacted to successive data readouts and product launches, with the stock advancing to well above USD 1,000 per share at its recent highs according to exchange quotations, placing it near the upper end of its one-year band.

Technical indicators followed by traders, such as moving averages based on recent closing prices, currently reflect a strong long-term uptrend in the stock, with shorter-term averages positioned above longer-term reference levels and the share price fluctuating around these support zones, while momentum measures like the relative strength index have periodically entered overbought territory during sharp rallies but have so far not signaled a sustained trend reversal.

Conclusion

The latest LIBRETTO-432 Phase 3 data disclosed on 05/31/2026 strengthens the strategic position of Retevmo within Eli Lilly’s oncology pipeline and demonstrates a pronounced reduction in disease recurrence or death in early-stage RET fusion-positive lung cancer, an area where adjuvant therapy options are evolving quickly.

Set against a backdrop of a high share price on the New York Stock Exchange and strong interest from US and international institutional investors, the new clinical results and the company’s existing metabolic portfolio help explain why the stock remains closely watched, while chart-based indicators show a pronounced long-term uptrend that traders and long-horizon shareholders alike will continue to monitor as regulatory discussions on the Retevmo data proceed.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.